Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.
NCT06899633 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 509
Last updated 2026-03-17
Summary
Multicenter, observational, descriptive study of the diagnosis, course and treatment of patients with SLE in routine practice in Kazakhstan: a registry study with retrospective and prospective components.
Conditions
- Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan
- Description of the Course of SLE in Patients in the Republic of Kazakhstan
- Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-15
- Primary Completion
- 2027-02-28
- Completion
- 2027-02-28
Countries
- Kazakhstan
Study Locations
More Related Trials
-
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
NCT05637112 ·Status: ACTIVE_NOT_RECRUITING
-
Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients
NCT06063668 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
NCT07102030 ·Status: RECRUITING
-
Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
NCT01559090 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163 ·Status: RECRUITING ·Phase: PHASE2
-
Transcriptional and Immune Parameters of Response to Belimumab
NCT04570306 ·Status: COMPLETED
-
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
NCT00624351 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
NCT06394063 ·Status: RECRUITING ·Phase: NA
-
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
NCT03003572 ·Status: RECRUITING
-
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
NCT06530849 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
NCT02554019 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
NCT01305746 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037 ·Status: RECRUITING ·Phase: PHASE1
-
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
NCT05845593 ·Status: RECRUITING
-
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
NCT07144514 ·Status: NOT_YET_RECRUITING
-
Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
NCT00660881 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806 ·Status: RECRUITING ·Phase: PHASE1
-
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
NCT05666336 ·Status: RECRUITING ·Phase: PHASE4
-
Gut Microbiota Dysbiosis in Lupus Nephritis
NCT06231303 ·Status: NOT_YET_RECRUITING
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
Autophagy in Systemic Lupus Erythematosus
NCT03583853 ·Status: UNKNOWN
-
Immunogenicity, Reactogenicity of Shingrix in SLE
NCT06001606 ·Status: UNKNOWN ·Phase: PHASE3
-
Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
NCT03958851 ·Status: UNKNOWN